免疫调定点抑制剂在肝癌肝移植患者中的应用

摘要/Abstract

摘要： 肝癌是恶性程度最高的实体肿瘤之一,肝移植治疗是其目前最有效的治疗方法。但是绝大部分患者初诊时已超出了肝移植标准,同时术后肿瘤复发也严重影响患者长期生存。目前免疫治疗是实体肿瘤治疗的新方向,可能使肝癌患者肿瘤得到良好的控制,以实现对肿瘤的降期或对复发肿瘤的清除。在本篇综述中,我们主要讨论免疫调定点抑制剂在肝移植前降期或桥接治疗,以及肝移植后肿瘤复发治疗中应用的现状以及目前研究的进展。

关键词: 肝癌, 肝移植, 免疫治疗

Abstract: Hepatocellular carcinoma (HCC) is one of the most malignant solid tumors. Liver transplantation is currently the most effective treatment for HCC. However, most of the patients have exceeded the transplantation standards when they are first diagnosed. Besides, the recurrence of tumors after surgery also seriously affects the long-term survival of patients who have accepted transplantation. Immunotherapy is a new treatment of solid tumors. Some HCC patients who received immunotherapy achieved tumor downgrading or elimination in previous reports. In this review, we mainly discuss current research progress of immune checkpoint inhibitors in the downstage or bridging therapy before liver transplantation, as well as in the treatment of recurrence cancer after liver transplantation.

Key words: Hepatocellular carcinoma, Liver transplantation, Immunotherapy

熊俊, 万赤丹. 免疫调定点抑制剂在肝癌肝移植患者中的应用[J]. 肝癌电子杂志, 2021, 8(3): 30-34.

Xiong Jun, Wan Chidan. Immune checkpoint inhibitors in liver transplantation patients with hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(3): 30-34.

参考文献

[1] SANTOPAOLO F, LENCI I, MILANA M, et al.Liver transplantation for hepatocellular carcinoma: Where do we stand?[J]. World J Gastroenterol, 2019, 25(21): 2591-2602.
[2] ADAM R, KARAM V, CAILLIEZ V, et al.2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation[J]. Transpl Int, 2018, 31(12): 1293-1317.
[3] PINNA A D, YANG T, MAZZAFERRO V, et al.Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma[J]. Ann Surg, 2018, 268(5): 868-875.
[4] YAO F Y, FERRELL L, BASS N M, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403.
[5] MAZZAFERRO V, LLOVET J M, MICELI R, et al.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1): 35-43.
[6] XU X, LU D, LING Q, et al.Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041.
[7] YAO F Y, BASS N M, NIKOLAI B, et al.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy[J]. Liver Transpl, 2003, 9(7): 684-692.
[8] MAJNO P, LENCIONI R, MORNEX F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? [J]. Liver Transpl, 2011, 17, Suppl 2:S98-108.
[9] ESCARTIN A, SAPISOCHIN G, BILBAO I, et al.Recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplant Proc, 2007, 39(7): 2308-2310.
[10] PLESSIER A, CODES L, CONSIGNY Y, et al.Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma[J]. Liver Transpl, 2004, 10(2 Suppl 1): S86-90.
[11] VERNA E C, PATEL Y A, AGGARWAL A, et al.Liver transplantation for hepatocellular carcinoma: Management after the transplant[J]. Am J Transplant, 2020, 20(2): 333-347.
[12] LIU D, JENKINS R W, SULLIVAN R J.Mechanisms of Resistance to Immune Checkpoint Blockade[J]. Am J Clin Dermatol, 2019, 20(1): 41-54.
[13] AI D, CHOO S P, CHEW V.Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers[J]. Cancers (Basel), 2019, 11(12): 1926.
[14] MAZZAFERRO V, CITTERIO D, BHOORI S, et al.Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21(7): 947-956.
[15] SAHIN I H, KHALIL L, MILLETT R, et al.Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook[J]. Chin Clin Oncol, 2021, 10(1): 7.
[16] TOPALIAN S L, TAUBE J M, PARDOLL D M. Neoadjuvant checkpoint blockade for cancer immunotherapy [J]. Science, 2020, 367(6477): eaax0182.
[17] O'DONNELL J S, HOEFSMIT E P, SMYTH M J, et al. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment[J]. Clin Cancer Res, 2019, 25(19): 5743-5751.
[18] LIU J, BLAKE S J, YONG M C, et al.Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease[J]. Cancer Discov, 2016, 6(12): 1382-1399.
[19] SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al.Immunotherapy as a Downstaging Therapy for Liver Transplantation[J]. Hepatology, 2020, 72(4): 1488-1490.
[20] TABRIZIAN P, FLORMAN S S, SCHWARTZ M E.PD-1 inhibitor as bridge therapy to liver transplantation?[J]. Am J Transplant, 2020, 21(5):1979-1980.
[21] NORDNESS M F, HAMEL S, GODFREY C M, et al.Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883.
[22] SHI X L, MANCHAM S, HANSEN B E, et al.Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6): 1274-1282.
[23] WANG D Y, JOHNSON D B, DAVIS E J.Toxicities Associated With PD-1/PD-L1 Blockade[J]. Cancer J, 2018, 24(1): 36-40.
[24] MUNKER S, DE TONI E N. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973.
[25] EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[26] YAU T, PARK J W, FINN R S, et al.LBA38_PR - CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Annals of Oncology, 2019, 30(5_suppl):v874-v875.
[27] ZHU A X, FINN R S, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[28] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[29] FINN R S, IKEDA M, ZHU A X, et al.Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[30] XU J, SHEN J, GU S, et al.Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[31] YUAN G, CHENG X, LI Q, et al.Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study[J]. Onco Targets Ther, 2020, 13(12):12683-12693.
[32] YARCHOAN M, ZHU Q, DURHAM J N, et al.Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)[J]. Journal of Clinical Oncology, 2021, 39(3_suppl): 335-335.
[33] 张雯雯, 胡丙洋, 韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 26(12): 947-948.
[34] SLOVAK R, LUDWIG J M, GETTINGER S N, et al.Immuno-thermal ablations - boosting the anticancer immune response[J]. J Immunother Cancer, 2017, 5(1): 78.
[35] DUFFY A G, ULAHANNAN S V, MAKOROVA-RUSHER O, et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551.
[36] LYU N, KONG Y, LI X, et al.Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study[J]. Front Oncol, 2020, 10(10):580241.
[37] CHAO J, ZHU Q, CHEN D, et al.Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection[J]. Front Oncol, 2021, 11(10):667555.
[38] WANG J, WANG J, WANG J, et al.Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report[J]. J Int Med Res, 2021, 49(2): 300060521994406.
[39] CHIANG C L, CHAN A C Y, CHIU K W H, et al. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy[J]. Front Oncol, 2019, 9(11):1157.
[40] LIOU H, MODY K, BOYLE A W, et al.Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive Hepatocellular Carcinoma Resulting in Complete Pathologic Response[J]. Hepatology, 2021, 74(1):525-527.
[41] FERNANDEZ-SEVILLA E, ALLARD M A, SELTEN J, et al.Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447.
[42] GOLDARACENA N, GORGEN A, DOYLE A, et al.Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation[J]. J Hepatol, 2019, 70(4): 666-673.
[43] MENON K V, HAKEEM A R, HEATON N D.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment PharmacolTher, 2013, 37(4): 411-419.
[44] GEISSLER E K, SCHNITZBAUER A A, ZULKE C, et al.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial[J]. Transplantation, 2016, 100(1): 116-125.
[45] MANCUSO A, MAZZOLA A, CABIBBO G, et al.Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis[J]. Dig Liver Dis, 2015, 47(4): 324-330.
[46] RAVAIOLI M, CUCCHETTI A, PINNA A D, et al.The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Sci Rep, 2017, 7(1): 11305.
[47] KITTAI A S, OLDHAM H, CETNAR J, et al.Immune Checkpoint Inhibitors in Organ Transplant Patients[J]. J Immunother, 2017, 40(7): 277-281.
[48] TANAKA K, ALBIN M J, YUAN X, et al.PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection[J]. J Immunol, 2007, 179(8): 5204-5210.
[49] KUMAR V, SHINAGARE A B, RENNKE H G, et al.The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature[J]. Oncologist, 2020, 25(6): 505-514.
[50] D'IZARNY-GARGAS T, DURRBACH A, ZAIDAN M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review[J]. Am J Transplant, 2020, 20(9): 2457-2465.
[51] AMJAD W, KOTIAH S, GUPTA A, et al.Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab[J]. J Clin Exp Hepatol, 2020, 10(2): 185-187.
[52] RAMMOHAN A, REDDY M S, FAROUK M, et al.Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?[J]. Hepatology, 2018, 67(3): 1166-1168.
[53] DELEON T T, SALOMAO M A, AQEL B A, et al.Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062.